Urology Search
Urology Urology

Conference Reports

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2020)

San Francisco, California, US
13 February 2020 - 15 February 2020

17th Urological Association of Asia Congress (UAA) 2019

07 August 2019 - 10 August 2019

Uro-Oncology Asia 2019

19 January 2019 - 20 January 2019

European Association of Urology (EAU) 2018 Congress

Copenhagen
16 March 2018 - 19 March 2018

2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2018)

San Francisco, California
08 February 2018 - 10 February 2018

Hong Kong Society of Uro-Oncology Annual Scientific Meeting 2018

Hong Kong
20 January 2018 - 20 January 2018

15th Urological Association of Asia Congress (UAA 2017)

04 August 2017 - 06 August 2017
Editor's Recommendations
Most Read Articles
Lower joint replacement risk yet another benefit of statins
2 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Vegan, vegetarian diets may increase susceptibility to depression
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Migraine a risk factor for dementia?
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis
Roshini Claire Anthony, 19 hours ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.